吴轩

字号 + –

04 9月 2019

1
2
3
4
5

Author : 伤口世界

从事影像导向下的肿瘤消融工作10余年，经验丰富，其带领的学科团队为省内较早开展肿瘤消融的学科，并为我市首批通过省内专家组评审并批准开展肿瘤消融技术的学科。累积开展甲状腺、肺、肝、胰腺、肾、盆腔等脏器肿瘤消融千余台。其中甲状腺结节消融百余台，从未发生不可恢复的严重并发症，并协助多家镇级医院开展甲状腺结节消融技术，深受好评。

东莞康华医院血管·肿瘤介入科学科负责人

•中国抗癌协会青委会委员
•广东省医学会介入分会委员
•广东临床医学会肿瘤微创诊疗专委会常委
•广东省中医药协会肿瘤分会委员
•海峡医学会肿瘤微创分会委员
•师从国内著名肿瘤微创介入专家罗鹏飞教授
•荣获东莞市“最美医生”、“最受市民欢迎医生”，东莞康华医院“十佳员工”等荣誉称号

Latest from 伤口世界

K2 Content

Diabetes remission in the real world 2024-09-20 00:00

Pam Brown

GP in Swansea

Citation: Brown P (2024) Diabetes Distilled: Diabetes remission in the real world. Diabetes & Primary Care 26: 145–7

Diabetes remission is achievable at scale in the real world, according to early results from the NHS Type 2 Diabetes Path to Remission programme published in Lancet Diabetes & Endocrinology. Of 7540 people referred to the programme between September 2020 and December 2022, a total of 1740 started the total diet replacement section of the programme before January 2022, and 960 (55%) completed the programme. Mean weight loss for the 1710 who started the programme and had follow-up data available was 9.4 kg (8.3%), with a mean weight loss of 10.3 kg (9.3%) among the 945 who completed the programme. Amongst the 945 who completed the programme and had two HbA1c measurements, 32% achieved remission, with mean weight loss of 15.9 kg (14.4%), while overall 27% of those who started the programme achieved remission regardless of whether they completed. Remission rates are lower than in trials such as DiRECT and DIADEM-I, despite similar levels of weight loss. The authors highlight that an additional 17% of participants met the HbA1c targets for remission but continued on metformin and may otherwise have achieved remission. These early results confirm that type 2 diabetes remission is indeed possible at scale in the real world, outside of clinical trials.
Impact of metformin timing on glucose and GLP-1 response 2024-09-19 00:00

Pam Brown GP in Swansea

Citation: Brown P (2024) Diabetes Distilled: Impact of metformin timing on glucose and GLP-1 response. Diabetes & Primary Care 26: 143–4

Glucose-lowering effects in response to normal-release metformin are greater when the drug is given 30 or 60 minutes before, rather than with, food, according to this small study in people with well-controlled type 2 diabetes published in Diabetologia. Endogenous GLP-1 secretion increased when metformin 1000 mg was given 30 or 60 minutes prior to a glucose infusion, whereas there was no increase when the metformin was administered at the same time as the glucose. The results suggest that, if tolerated, administering standard release metformin before meals may lead to improved postprandial glycaemic control.
The importance of getting the correct diabetes diagnosis 2024-09-18 00:00

Jane Diggle Specialist Diabetes Nurse Practitioner, West Yorkshire

Citation: Diggle J (2024) The importance of getting the correct diabetes diagnosis. Diabetes & Primary Care 26: 111–2

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长

吴轩

Latest from 伤口世界

学术会议

伤口世界提示

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长

吴轩

Latest from 伤口世界

消息订阅

学术会议

伤口世界提示